Ian Krop, MD, PhD

Articles by Ian Krop, MD, PhD

Unmet Needs and Future Direction in HER2+ Breast Cancer

ByJoyce A. O'Shaughnessy, MD,Melinda L. Telli, MD,Aditya Bardia, MD, MPH, FASCO,Ian Krop, MD, PhD,Kandace McGuire, MD

July 29th 2024

The panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.

Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC

ByJoyce A. O'Shaughnessy, MD,Melinda L. Telli, MD,Aditya Bardia, MD, MPH, FASCO,Ian Krop, MD, PhD,Kandace McGuire, MD

July 29th 2024

Focusing on the selection of subsequent therapies for patients with HER2-low/HER2+ metastatic breast cancer, the panel discusses treatment sequencing considerations and practices.

Clinical Perspectives on Managing ILD Related to T-DXd

ByJoyce A. O'Shaughnessy, MD,Melinda L. Telli, MD,Aditya Bardia, MD, MPH, FASCO,Ian Krop, MD, PhD,Kandace McGuire, MD

July 22nd 2024

Breast cancer specialists discuss adverse events associated with T-DXd, focusing on monitoring for interstitial lung disease (ILD) and the role of re-challenging patients with T-DXd after resolution of grade 1 ILD.

Overview of DESTINY-Breast06

ByJoyce A. O'Shaughnessy, MD,Melinda L. Telli, MD,Aditya Bardia, MD, MPH, FASCO,Ian Krop, MD, PhD,Kandace McGuire, MD

July 22nd 2024

Aditya Bardia, MD, MPH, shares comprehensive insights on the DESTINY-Breast06 study evaluating T-DXd in HER2-low and HER2 ultra-low metastatic breast cancer, and the panel offers its initial impressions.

Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges

ByJoyce A. O'Shaughnessy, MD,Melinda L. Telli, MD,Aditya Bardia, MD, MPH, FASCO,Ian Krop, MD, PhD,Kandace McGuire, MD

July 15th 2024

Ian Krop, MD, PhD, provides an overview of HER2-low and HER2 ultra-low breast cancer and discusses challenges encountered during diagnosis.

Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets

ByJoyce A. O'Shaughnessy, MD,Melinda L. Telli, MD,Aditya Bardia, MD, MPH, FASCO,Ian Krop, MD, PhD,Kandace McGuire, MD

July 15th 2024

Experts on breast cancer discuss the potential impact of ongoing research in HER2+ breast cancer, highlighting how results from the DESTINY-Breast07 study may translate to DESTINY-Breast09.

Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer

ByJoyce A. O'Shaughnessy, MD,Melinda L. Telli, MD,Aditya Bardia, MD, MPH, FASCO,Ian Krop, MD, PhD,Kandace McGuire, MD

July 8th 2024

Melinda Telli, MD, provides an overview of ongoing research in HER2+ metastatic breast cancer, highlighting the DESTINY-Breast09, PATINA, INAVO122, and HER2CLIMB-05 studies.

Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC

ByJoyce A. O'Shaughnessy, MD,Melinda L. Telli, MD,Aditya Bardia, MD, MPH, FASCO,Ian Krop, MD, PhD,Kandace McGuire, MD

July 8th 2024

The panel provides comprehensive insights on approaching first-line treatment of patients with HER2+ metastatic breast cancer and the role of neratinib.

Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer

ByJoyce O’Shaughnessy, MD,Melinda L. Telli, MD,Aditya Bardia, MD, MPH, FASCO,Ian Krop, MD, PhD,Kandace McGuire, MD

July 1st 2024

Breast cancer specialists outline their institution’s practices regarding the choice between subcutaneous fixed-dose pertuzumab – trastuzumab-hyaluronidase and intravenous pertuzumab and trastuzumab.

Preoperative Monitoring and Surgical Options for HER2+ Patients

ByJoyce O'Shaughnessy, MD,Melinda L. Telli, MD,Aditya Bardia, MD, MPH, FASCO,Ian Krop, MD, PhD,Kandace McGuire, MD

July 1st 2024

Kandace P. McGuire, MD, provides clinical insights on how patient monitoring practices inform discussions around surgical options, providing the potential for deescalating surgical management.

Neoadjuvant Treatment Options in HER2+ Early Breast Cancer

ByJoyce O’Shaughnessy, MD,Melinda L. Telli, MD,Aditya Bardia, MD, MPH, FASCO,Ian Krop, MD, PhD,Kandace McGuire, MD

June 24th 2024

Ian Krop, MD, PhD, outlines his institution’s approach to utilizing neoadjuvant therapy in patients with HER2+ early breast cancer, and Melinda Telli, MD, discusses the role of surgery.

Challenges in Diagnosing HER2+ Breast Cancer

ByJoyce O’Shaughnessy, MD,Melinda L. Telli, MD,Aditya Bardia, MD, MPH, FASCO,Ian Krop, MD, PhD,Kandace McGuire, MD

June 24th 2024

A panel of experts on breast cancer provide insights on challenges encountered during the diagnosis of HER2+ early breast cancer and discuss the role of immunohistochemistry and FISH testing.